Drug Trial Radar · NCT07765524
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Mar 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary objectives are to assess the safety of FKC289 and to establish the recommended Phase II dose (RP2D). And this Phase II study is designed to evaluate the efficacy of FKC289.The primary objectives are to assess proportion of subjects with hematologically best complete response (CR) within 6 months.
Conditions
- Primary Light Chain (AL) Amyloidosis
Interventions
FKC289 infusionDrug
Anti-BCMA/CD19 chimeric antigen receptor autologous T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT)Time frame: Within 28 days after FKC289 infusion
- Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Within 24 months after FKC289 infusion
- Replication Competent Lentivirus (RCL)Time frame: Within 24 months after FKC289 infusion
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The Frist Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The Frist Affiliated Hospital of Guangxi Medical university
Nanning, Guangxi, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Tongji Mecial college of HUST
Wuhan, Hubei, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
West China Hospital Sichuan Hospital
Chengdu, Sichuan, China
The Second Affiliated Hospital Zhejiang University school of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.